All In Biotech

Drug Trial Radar · NCT02667938

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

Last checked: Nov 19, 2026Latest source record: Oct 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

Mar 2015

Primary completion

Jan 2016

Study completion May 2016

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • HCP1303 capsule 5/0.2mgDrug

  • HCP1303 capsule 5/0.4mgDrug

  • HGP1201Drug

  • HCP1303 capsule 5/0.2mg placeboDrug

  • HCP1303 capsule 5/0.4mg placeboDrug

  • HGP1201 placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Total IPSS (International Prostate Symptom Score)Time frame: baseline and 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.